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Abstract 
Supramolecular biovectors (SMBV) are nanoparticular drug carriers composed of an internal crosslinked solid core externally grafted 
with fatty acids and surrounded with a phospholipid layer. We show in this paper that the internal core can be derivatized with anionic 
ligands such as phosphate in order to allow the efficient entrapment of cationic molecules through a process akin to ion exchange. 
Synthesis of SMBV involved first a cross linking and derivatization step of polysaccharides followed by a homogenization, a drying and a 
regioselective acylation step. Acylated polysaccharide cores are thus obtained which can be loaded with drugs and wrapped with a 
phospholipid layer. The SMBVs obtained are characterized through their size, 20 nm, and their ability to filter through 0.22 /xm pore size 
membrane. Gel permeation chromatography experiments performed with various phospholipid/acylated cores ratios indicate that SMBVs 
lbrm entities distinct from liposomes and that the optimum phospholipid/acylated cores ratio for this specific type of SMBVs is close to 
100%. The supramolecular structure of SMBVs and in particular the spatial proximity between acylated cores and phospholipids is 
demonstrated through resonance energy transfer experiments. The drug loading capability of SMBVs is illustrated by the preparation of 
gentamicin and doxorubicin loaded SMBV. The therapeutic potential of SMBVs is then discussed notably in the light of a possible 
biomimetism with low density lipoproteins (LDL). 
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1. Introduction 
The therapeutic interest of nanoparticular and 
nanovesicular drug carriers for the targeting of pharmaco- 
logically active drugs has been largely documented in the 
general and patent literature [I]. Although an impressive 
amount of work has been devoted to the study of these 
systems and notably of liposomes [2,3], practical applica- 
tions are still extremely limited. This situation stems from 
the fact that existing carriers still present a number of 
serious shortcomings such as shelf and plasmatic stability, 
lack of reproducibility, low drug entrapment capability, 
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inadequate pharmaceutical definition and, in some cases, 
lack of biocompatibility. In addition, none of the existing 
synthetic carriers have been shown to have a limited 
ability to cross the blood vessel linings and therefore, their 
targeting capabilities following intravenous injections are 
mainly restricted to the blood compartment. 
To solve this last problem, the use of natural carriers 
such as LDLs has been suggested [4]. Indeed, LDLs 
present some very interesting properties uch as systemic 
diffusion from the blood stream and the fact that they can 
be internalized in specific cells through a high affinity 
receptor mediated endocytosis [5]. We [6-8] and others 
[9-11] have proposed LDLs as a useful discriminatory 
vehicle for the delivery of cytotoxic drugs to tumour cells 
on the basis of a higher uptake of LDLs by these tissues. 
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Because of their lipidic structure, LDLs have however a 
drug entrapment capability which is restricted to lipophilic 
molecules. In addition, attempts to achieve drug loading 
ratios compatible with therapeutic applications have gener- 
ally led to alterations of the physical integrity of the LDLs 
and loss of their original diffusion and targeting properties 
[12]. It would be, therefore, particularly interesting to 
dispose of biomimetic synthetic particles with the ability to 
entrap efficiently hydrophilic molecules while maintaining 
the outstanding metabolic properties of LDLs. We have 
reported [13] previously the design and the synthesis of a 
new family of synthetic nanoparticles biomimetic of the 
lipidic part of LDL, the supra molecular biovectors 
(SMBVs). 
We wish now to address the problem of ionic drugs 
entrapment in SMBVs and we are describing in this paper, 
the synthesis and characterization f SMBVs specially 
designed for this purpose. The SMBVs are nanoparticles 
composed of an internal core of cross linked polysaccha- 
ride externally grafted with fatty acid and surrounded by a 
layer of phospholipids. SMBVs are then constituted by a 
hydrophilic internal core surrounded by a lipophilic exter- 
nal layer and have thus the theoretical ability to entrap 
both hydrophilic and lipophilic molecules. The internal 
volume of small diameter particles is however very small 
and conventional entrapment techniques are thus bound to 
be poorly efficient in terms of entrapment yield and entrap- 
ment ratio. We have thus selected instead to apprehend the 
problem of drug entrapment in terms of partition coeffi- 
cient of the drug between SMBVs and the surrounding 
aqueous medium. The selection of SMBVs with suitable 
partition coefficient may be approached using chromato- 
graphic considerations. Chromatographic matrices are usu- 
ally constituted of microporous particles derived with spe- 
cific ligands. Numerous ligands have been employed for 
the synthesis of these matrices which therefore xhibit a 
large array of possibilities of physico-chemical interac- 
tions. The chromatographic behaviour of a molecule and 
notably its retention on a column is directly linked to its 
partition coefficient, K, between the chromatographic ma- 
trix and the surrounding medium, i.e., the mobile phase 
[14]. This is notably expressed by the measure of the 
capacity factor k' which is equal to K × (~p/V~p) where 
V,p is the volume of the stationary phase and Vmp the 
volume of the mobile phase, k' is also equal to (V~- 
Vo)/V o, where V r is the elution volume of the solute and 
V 0 is the void volume of the column. Materials with 
suitable partition coefficient, in a given medium, may, 
then, be easily deduced from chromatographic data. 
Analysis of drug chromatographic data [15] indicates 
that, indeed, water soluble ionic drugs are, as expected, 
only weakly retained on hydrophobic reverse phase 
columns and would have, accordingly, unfavourable parti- 
tion coefficients in LDLs. Those drugs, however, when 
sufficiently ionic, are found to be strongly retained on 
opposite charge ion exchange columns. For those drugs, 
the use of materials analogous to ion exchange matrices 
might hen solve the problem of the entrapment efficiency. 
This principle has, in fact, already been used for the 
entrapment of ionic cytotoxic agents and notably doxoru- 
bicin within ion exchange microspheres [ 16,17] and acrylic 
acid nanoparticles [18]. 
We have then undertaken to synthesize a specific type 
of SMBVs characterized by the presence of ionic ligands 
grafted upon the polysaccharide n twork. We describe here 
the synthesis of anionic SMBVs, their characterization a d 
their potential for cationic drugs entrapment. 
2. Materials and methods 
2.1. Chemicals 
Soluble starch (Prolabo, France); POC13 (Prolabo, 
France), palmitoyl chloride (Fluka); egg yolk phospha- 
tidylcholine (EYPC) (Lipoid, Germany); cholesterol 
(Sigma, France); octyl glucopyranoside (OGP) (Sigma); 
rhodamine isothiocyanate (Molecular Probe); rhodamine 
dipalmitoylphosphatidylethanolamine (Molecular Probe); 
NBD dipalmitoylphosphatidylethanolamine (Mol cular 
Probe); dicyclohexylcarbodiimide (DCCI) (Fluka); 
[14C]palmitic acid 53.7 mCi/mmol (CEA Saclay, France); 
4-dimethylaminopyridine (DMAP) (Fluka, France); scintil- 
lation liquid cocktail (Ready safe Beckman, France); gen- 
tamicin (Sigma); doxorubicin (Carlo Erba). All others 
chemicals and solvents were commercially available and at 
least reagent grade. 
2.2. Equipments 
Radioactivity measurements were performed on a 
Packard Tri-Carb 460 CD (Packard Instrument SA, France). 
The HPLC system was composed of a model 302 Gilson 
pump, a Rheodyne model 71-25 injector and a model 802 
C Gilson manometric module. Detection was performed 
either with a refractive index detector Gilson, a fluorescent 
detector Shimadzu (RF 551) or an evaporating light scat- 
tering detector (DDL 21 Eurosep Instrument). Energy 
transfer experiments were performed with a F 2000 Hi- 
tachi spectrofluorimeter (Tokyo, Japan). A Coulter N4 MD 
nanoparticles analyser (Coultronics, Margency, France) was 
used to determine the diameter of liposomes and SMBVs. 
Bath sonications were performed with a Transonic 460 
(Elma) and probe sonications with a Vibracell Instrument 
(Bioblock). High pressure homogenization was carried out 
with a Minilab (Rannies, Denmark). 
2.3. Preparation of SMBVs 
SMBVs are synthesized as described by Samain et al. 
[191. 
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Step 1: preparation of 20 nm anionic polysaccharide 
particles 
100 g of soluble starch are introduced in a 3 1 reaction 
vessel fitted with mechanical stirring. 500 ml of NaOH 2 
M are then introduced in the flask and the mixture is 
stirred until complete homogenization is obtained. The 
temperature of the flask is then adjusted to 4 ° C and POC13 
(50 g, 0.32 M) is added dropwise together with a solution 
of NaOH 10 M (150 ml). When the addition is completed, 
the reaction is stirred for an additional 15 min then brought 
to pH 7 through the addition of chlorohydric acid. The 
resulting el is diluted in 2 1 of distilled water and homog- 
enized at 800 bars with a high pressure homogenizer, until 
particles with a diameter around 20 nm are obtained. The 
polysaccharide particles are then precipitated by the addi- 
tion of 2 1 of EtOH, filtered, washed with 2 × 500 ml of 
EtOH, suspended in 4 1 distilled water or 7 1 of a 20 g/ l  
NH4HCO 3 solution and freeze-dried to afford 70 g of dry 
polysaccharide cores. 
Step 2: preparation of acylated cores 
10 g of the dry polysaccharide cores obtained previ- 
ously are introduced in a 100 ml round bottom flask fitted 
with magnetic stirring and a reflux condenser and contain- 
ing 1.7 g of palmitoyl chloride dissolved in 30 ml of 
CH2C12. The reaction is stirred energetically and refluxed 
overnight. The solvent is then evaporated under vacuum 
with a rotary evaporator. The residue is suspended in 50 
ml of diethyl ether, filtered, washed with 2 × 50 ml of 
ethanol and dried under vacuum to afford 10.3 g of 
acylated particles. 10 g of the acylated cores are then 
resuspended in 300 ml of distilled water or in 300 ml of a 
20 g / l  ammonium bicarbonate solution, freeze-dried, re- 
suspended in 50 ml of CH2CI z and reacylated as described 
previously. The material obtained is then submitted to a 
third and a fourth acylation cycle. 
The rhodamine labelled acylated cores are synthesized 
from acylated cores as follows. Rhodamine isothiocyanate 
(1 mg) dissolved in 10 /~1 of DMF is added to acylated 
cores (100 mg), dispersed in 2 ml of Na2CO 3, 50 mM, pH 
10 buffer. The reaction mixture is maintained for 15 hours 
at room temperature in the dark. The rhodamine labelled 
acylated cores are then precipitated with excess EtOH, 
filtered, washed with EtOH until complete limination of 
excess free rhodamine and dried under vacuum. 
For the preparation of the ~4C-radiolabelled core, DCCI 
(0.93 mg) dissolved in (500 /xl) of CH2C12 is added to 
[14C]palmitic acid (500 /zCi) in a well-stoppered 5 ml 
flask fitted with magnetic stirring. The reaction is then 
stirred vigorously for 24 h at 4 ° C to afford [14C]palmitic 
acid anhydride which is used without further purification. 
DMAP (0.55 mg) and acylated cores (100 mg) are added 
to the anhydride solution and the reaction mixture is stirred 
vigorously at room temperature for 24 h. The 14C-acylated 
cores are then filtered, washed with 3 × 5 ml of diethyl 
ether and 3 × 5 ml of ethanol, resuspended in water and 
freeze-dried. 
Step 3: establishment ofthe phospholipid layer 
The acylated cores (5 mg) are mixed with phospholipids 
(5 mg) and thoroughly dispersed in 2 ml of 50 mM OGP. 
The resulting mixture is then diluted rapidly with 4 ml of 
water and submitted to extensive dialysis at 4 ° C. For the 
control experiments, liposomes are prepared through the 
same process. 
Fluorescent labelled SMBVs are prepared by the deter- 
gent dialysis technique using the previously obtained rho- 
damine labelled acylated cores or a phospholipid composi- 
tion containing 0.1% (w/w) of NBD phosphatidylethanol- 
amine or rhodamine phosphatidylethanolamine. 
~4C-radiolabelled SMBVs are prepared from ~4C-radio- 
labelled acylated cores, using the same detergent dialysis 
technique as the one described for the preparation of cold 
SMBVs. 
After extensive dialysis, the fluorescent and J4C-labelled 
SMBVs are submitted to a last purification step through 
Sephadex PD 10 chromatography. 
2.4. Analytical characterization fSMBVs 
Determination of the ratio of phosphate grafting 
The ratio of phosphate grafting is determined by titra- 
tion of the polysaccharide particles with 0.1 M NaOH, 
using phenolphthaleine as a pH indicator. 
Quantification of fatty acids 
The percentage of fatty acids covalently linked to the 
polysaccharide cores is determined by HPLC after saponi- 
fication. 100 mg of acylated cores are first dispersed by 
sonication in 10 ml dichloromethane. 10 ml of methanol 
and 2 ml of NaOH 2 M are then added. The suspension 
obtained is then stirred during three days. Hydrolyzed fatty 
acids are extracted by dichloromethane after acidification 
by HC1 2 M. The organic phase is evaporated and the 
residue is solubilized in 10 ml of methanol. Quantification 
is achieved by HPLC with evaporating light scattering 
detection. The HPLC system used is a reverse phase 
system (Nucleosil C18 5 /xm, 15 cm) with a mobile phase 
0.1% TFA in methanol. The flow rate is 1 ml/min. 
Size determination 
The size of SMBVs is measured with a photon correla- 
tion laser light-scattering method. Mean value and standard 
deviation for the overall particle size distribution are deter- 
mined. It has not proved possible to measure the size of 
fluorescent-labelled SMBV and doxorubicin loaded SMBV 
due to the interference of the fluorescence with the mea- 
surement. 
Gel permeation chromatography 
The rhodamine fluorescent labelled SMBVs and the 
rhodamine fluorescent labelled liposomes are analyzed by 
52 l. De Miguel et al./ Biochimica et Biophysica Acta 1237 (1995) 49-58 
column chromatography on a TSK PW 6000 column 30 
cm (Tokyo Soda, Tokyo, Japan) as previously described 
[20,21]. All chromatographic runs are made at room tem- 
perature and with a spectrofluorometric detector• The mo- 
bile phase consisted of Tris-HC1 10 mM pH 7.4, NaCI 120 
mM, sodium azide 0.2% with a 0.3 mi/min flow rate. 
Samples are detected in the eluate by fluorescence mis- 
sion at 580 nm after excitation at 520 nm. 
Resonance fluorescence nergy transfer study 
These studies have been carried out on SMBVs pre- 
pared from rhodamine labelled acylated cores and from 
NBD labelled phospholipids. The amount of energy trans- 
fer between the two fluorophores i measured by compari- 
son with mixtures of rhodamine labelled acylated cores 
and liposomes prepared independently from NBD labelled 
phospholipids. The fluorescence mission of NBD at 530 
nm following excitation at 470 nm, was measured for the 
various preparations of SMBVs, acylated cores and lipo- 
somes. The efficiency of energy transfer (E) was calcu- 
lated using the following equation: E = (1 - F /F  o) X 100 
where F is the fluorescence of the NBD in the assay in 
presence of rhodamine and F o is the fluorescence of NBD 
in a similar assay in absence of rhodamine. The energy 
transfer was also followed through the appearance of the 
rhodamine fluorescence mission at 580 nm following 
NBD excitation at 470 nm. 
2.5. Drugs entrapment within SMBVs 
Gentamicin 
Gentamicin (10.5 mg) is added to 35 mg of anionic 
acylated cores, dispersed in 1 ml distilled water. The 
preparation is stirred overnight, and then dispersed in 14 
ml of 50 mM OGP containing 28 mg of EYPC and 7 mg 
of cholesterol. The resulting mixture is then brought o pH 
8.5, through the addition of diluted NaOH, and diluted 
rapidly with 28 ml of pH 8.5 aqueous solution. Non 
entrapped gentamicin and the detergent are then removed 
by sequential uitrafiltration. The amount of non entrapped 
gentamicin is determined by difference through the mea- 
sure of the amount of free gentamicin determined by 
antimicrobial ssay. Briefly, the assay is performed through 
the measure of the area of inhibition of the growth of BS 
(ATCC6633) grown on an agar medium (bio-gelytone 6 g, 
yeast extract 3 g, beef extract 1.5 g, agar 15 g for a liter of 
distilled water. The pH of the medium is then adjusted to 
7). 
Doxorubicin 
Doxorubicin (200 mg) dissolved into 10 ml of distilled 
water is slowly added to a suspension of anionic acylated 
cores (500 mg) in 10 ml of ethanol. The mixture obtained 
is then stirred for two hours at room temperature and 
protected from light. Ethanol (10 ml) is then added to the 
suspension, the acylated cores are recovered by centrifuga- 
tion (10000 × g-15 rain) and dried. The dry residue of 
doxorubicin loaded acetylated cores is taken up with 175 
ml of 50 mM OGP containing 375 mg of 80:20 (w/w)  
EYPC/cholesterol and dispersed in an ultrasonic bath. The 
suspension obtained is then injected under an ultrasonic 
probe into 700 ml of distilled water. The SMBVs loaded 
with doxorubicin thereby formed are dialyzed extensively 
at 4 ° C to remove the detergent and then sterilized by 
filtration on 0.2 /zm filters. The doxorubicin is assayed by 
HPLC as previously described [22] except hat the detec- 
tion is performed with an UV detector at 240 nm. The 
incorporated Doxorubicin is determined after release by 
incubation of the SMBVs in a 2 M NaH2POJethanol 
(70:30) solution and ultrafiltration through a 50 kDa mem- 
brane. 
3. Results 
3.1. Synthesis of SMBVs 
The crosslinking of soluble starch, characterized by a 
mean molecular weight of 4000, with POCi 3 followed by a 
homogenization step, gives rise with 70% yield to a 
monodispersed population of about 20 nm particles (Fig. 
1). The ionic functionalization (1.53 mmol/g)  of these 
polysaccharide cores was determined by titration (data not 
shown) [23]. These results indicate the presence of a 
phosphate group for every 3.5 glucose residues. 
The acylation of these polysaccharide cores was carried 
out in CH2C1 z after freeze drying performed convention- 
ally or in the presence of NH4HCO 3. The polysaccharide 
cores were submitted to several cycles of acylation sepa- 
rated by hydrating and drying steps. The results are pre- 
sented in Fig. 2 and indicate that only a slight percentage 
of fatty acids can be grafted in the absence of NH4HCO 3, 
even after several acylation steps. When the drying, how- 
ever, is conducted in presence of NH4HCO 3, the resulting 
percentage of fatty acids is higher and increases with the 
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Fig. |. Size histogram ofanionic polysaccharide cores. 
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Fig. 2. Dependence of the fatty acid/polysaccharide cores ratio upon the 
number of acylation cycles and upon the presence of NH4HCO ~ during 
drying. After the acylation step, the particle are washed and the amount 
of fatty acids grafted upon the polysaccharide cores was determined by 
HPLC following extensive saponification of the acylated particles as 
described in Materials and methods. Presented ata are averages of 
triplicate measurement. 
number of acylations until reaching a plateau after the 
third. 
The phospholipid layer was established through the 
detergent dialysis technique using the dialysable detergent, 
octyl glucopyranoside [24]. The resulting preparations ob- 
tained with various phospholipids/acylated cores ratios, 
were then analyzed by photon correlation light scattering 
and by gel permeation chromatography. 
3.2. Determination of the optimum phospholipid / acylated 
core ratio 
The diameter of SMBVs prepared with various poly- 
saccharide/acylated core ratios and control iposomes pre- 
pared with the same technique was measured by photon 
correlation light scattering. The results presented in Table 
I indicate that, in the presence of phospholipids, 20 nm 
species are obtained. Liposomes prepared in the same 
conditions with the same phospholipidic composition, ex- 
hibit however also a 20 nm diameter and therefore may 
then be also present in the preparation. It is thus not 
possible to deduce from this experiment the amount of 
phospholipids actually associated with the acylated cores. 
The chromatographic analysis of SMBV was performed 
on a TSK PW 6000 column able to include particles with a 
diameter ange between 10 and 500 nm. Fluorescent la- 
belled SMBVs and fluorescent labelled liposomes were 
prepared by using phospholipid composition containing 
0.1% of rhodamine phosphatidylethanolamine. Th  results 
Table 1 
Study of SMBVs as a function of the phospholipid/acylated core ratio 
Phospholipid/acylated Size diameter 
core ratio (w/w)  (nm) 
0 > 1000 
0.50 18_+4 
0.75 19_+5 
1.00 18+3 
1.50 19+_5 
2.00 19+_5 
2.50 20+_5 
Control iposomes 20 +- 5 
SMBVs were prepared with various phospholipid/acytated core ratios 
and the diameter of the resulting preparations was measured by photon 
correlation light scattering. The phospholipid composition used was 
EYPC/cholesterol (80:20, w/w). The results indicate that the presence 
of phospholipids i  necessary for the obtention of 20 nm entities (n = 3). 
are presented in Fig. 3. The trace A indicates that lipo- 
somes are eluted as a major peak with a 33 min retention 
time. The results presented on trace E with SMBVs pre- 
pared with a phospholipid/acylated cores ratio of only 0.5 
indicate that the 33 min peak of liposomes is not observed 
A 
D 
E 
I I I I 
0 10 20 30 40 
Retention time (mn) 
Fig. 3. Gel permeation analysis of fluorescence labelled SMBVs. SMBVs 
prepared with various rhodamine labelled phospholipids/acylated cores 
ratios and control liposomes are analyzed by high performance gel 
permeation chromatography. Column TSK G 6000 PW: mobile phase: 
Tris-HCl 10 raM, NaC] 120 raM, azide 0.2 g/l, pH 7.4, fluorescence 
detection (exc. 540 nm, era. 580 nm). In order to allow a better 
comparison, the various chromatographic profiles are stacked upon each 
other. Trace A, control liposome. Trace B, acylated core ratio: 3. Trace C, 
acylated core ratio: 2. Trace D, acylated core ratio: I. Trace E, acylated 
core ration: 0.5. The results indicate that liposomes appear above a 
phospholipid/acylated cores ratio of I. 
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Table 2 
Filtration yields on 0.45 and 0.22 /xm membrane of J4C-labelled SMBVs 
Before filtration After filtration 
0.45 /xm 0.22 /xm 
SMBV 14C (dpm) 3055 -+ 155 3010-+ 175 2687 -+ 128 
SMBV recovery (%) - 100 89.5 
14C-labelled SMBVs were filtered through 0.45 and 0.22 /xm mem- 
branes. The radioactivity of the preparations was measured before and 
after filtration (n = 3). 
and that, instead, a single peak is observed with a 25 rain 
retention time. These results suggest hat l iposomes are not 
present in this preparation and that only SMBVs are 
observed. These results are confirmed by the study of 
traces D, C and B which analyzed SMBVs prepared with 
increasing phosphol ip id/acylated cores ratios. As ex- 
pected, increased l iposome peak areas corresponding to the 
excess of phospholipids are observed in these preparations. 
Trace D with a phosphol ip id/acylated cores ratio of 1 
shows the presence of a small amount of l iposomes. Traces 
C and B with a phosphol ip id/acylated cores ratio of 2 and 
3 show the presence of a much larger amount of iipo- 
somes. These results suggest hat the optimal ratio between 
phospholipids and acylated cores for these specific SMBSs 
is close to 1. 
4000" 
"~ 3500- 
30~ i
2500 
2000~ 
1500. 
1000. 
500" 
l ~ NBD-SMBV 
400 450 500 550 600 650 700 
~, (rim) 
NBD exc em 
Rhodamine exc em 
Fig. 4. Resonance energy transfer experiments. NBD-SMBV are prepared 
from acylated cores and NBD phospholipids. NBD-rhodamine-SMBV are 
prepared from rhodamine acylated cores and NBD phospholipids. Excita- 
tion of NBD-SMBV at 470 nm leads to the normal NBD emission at 530 
nm while excitation of NBD-rhodamine-SMBV leads to a quenching of 
NBD emission and to a rhodamine mission at 580 nm. Presented ata 
are typical of triplicate xperiments. 
3.3. SMBVs  character izat ion 
The SMBVs obtained previously were characterized by 
their ability to filter through 0.45 and 0.22 /.Lm membrane, 
their stability and by fluorescence nergy transfer studies. 
The filtration yield of SMBVs on a 0.45 and 0.22 /xm 
membrane has been investigated through the use of radio- 
labelled acylated cores. The labell ing was carried out by 
performing an additional acylation step with [lnC]palmitic 
acid. The filtration yield was determined by measuring the 
radioactivity of the preparation before and after filtration 
on the membranes. The results are presented in Table 2 
and indicate an almost quantitative filtration yield. These 
results suggest hat filtration through 0.22 /xm membranes 
may be used for the obtention of sterile SMBVs prepara- 
tions. 
SMBVs and l iposomes amples were prepared and ster- 
il ized by 0.22 /zm filtration and kept at 4 and 20 ° C. The 
size of the dispersions was measured at regular intervals 
and the results are presented in Table 3. At both tempera- 
tures, SMBVs are remarkably stable showing no sign of 
size increase or aggregation over time. On the other hand, 
l iposomes appear to aggregate heavily after a few months. 
Fluorescence nergy transfer studies have been carried 
out on SMBVs prepared from rhodamine labelled acylated 
cores and from NBD labelled phospholipids. The amount 
of energy transfer between the two fluorophores is quanti- 
tatively measured by fol lowing the decrease in the NBD 
Table 3 
Comparative SMBVs and liposomes tability as a function of time 
Size diameter (nm); time (months) 
1 2 3 5 6 7 8 12 
4°C SMBVs 18 +4 18 +4 19 ± 3 18__+ 4 19___ 5 19+ 3 20+4 23 +4 
liposomes 21 _-t-_ 5 31 -+ 5 32 ± 6 Agg a 
25 ° C SMBVs 19 -+ 4 19 -+ 3 18 _+ 3 n.d. b n.d. b 22 + 4 20 + 4 n.d. b 
liposomes 22 ± 3 22 + 4 Agg a 
SMBVs and liposomes were prepared with the same phospholipid composition EYPC/cholesterol (80:20, w/w), the same lipidic concentration (0.5 
mg/ml), the same process (dialysis of detergent). The preparations were measured at regular intervals by photon correlation light scattering. The 
phospholipid/acylated core ratio used for the preparation ofSMBVs was 1.5 (w/w). SMBVs appear to exhibit a superior stability compared to liposomes 
(n = 3). 
Aggregates. 
Not determined. 
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emission at 530 nm following NBD excitation at 470 nm. 
The results are compared with those obtained with mix- 
tures of rhodamine-labelled acylated cores with liposomes 
prepared from NBD labelled phospholipids. The results 
obtained indicate that up to 12% of energy transfer is 
observed with SMBVs while only 1.2% is observed with 
the mixture of acylated cores and liposomes. These results 
are in good agreement with the appearance of the rho- 
damine emission at 580 nm following NBD excitation at 
470 nm (Fig. 4) 
3.4. Drugs entrapment 
Drug entrapment is performed through a single incuba- 
tion step between acylated cores and the drug in aqueous 
or ethanol/water solutions. The incubation step is fol- 
lowed by a codispersion with phospholipids and OGP, then 
by a rapid dilution under the critical micellar concentration 
(CMC) of the detergent and finally by an extensive dialy- 
sis. The results obtained with gentamicin and doxorubicin 
are presented in Table 4. These results indicate that an 
almost quantitative entrapment yield can be obtained with 
gentamicin with a 14% entrapment ratio. Doxorubicin, on 
the other hand, is entrapped with a lower efficiency with a 
70% yield and with a 10% entrapment ratio. 
4. Discussion 
The design of a drug carrier intended for therapeutic 
uses and notably for parenteral administration, has to 
follow a strict set of guidelines concerning toxicity, possi- 
bility of industrial manufacturing, structure characteriza- 
tion, stability and drug entrapment efficiency. The results 
obtained with SMBVs will then be discussed with these 
considerations in mind. 
Although several starting materials, such as acrylic acid 
[18] or cellulose [23] are available to prepare ionic matri- 
ces, we decided, early on, that the use of those materials 
would inevitably arises concerns about their toxicity and 
biodegradability and we have accordingly selected a known 
biocompatible material, starch, for the synthesis of 20 nm 
ionic cores. Beside its biocompatibility, starch, like all 
polysaccharides, exhibits a high number of reactive hy- 
droxyl groups allowing easy chemical derivatization [25] 
such as cross linking or acylation and appears then to be a 
particularly appropriate material for the synthesis of SM- 
BVs. Starch is composed of homopolymers of glucose 
with various degree of branching [26] and thus cross 
linking is necessary in order to achieve a stable three-di- 
mensional structure. Numerous methods have been de- 
scribed to achieve cross linking of polysaccharides, the 
best known being through the use of epichlorhydrin [27] 
employed notably in the preparation of Sephadex particles. 
Epichlorhydrin gives rise to a glycerol-ether link between 
two glucose units and concern may be raised about the 
biodegradability of the ether linkage. In addition the result- 
ing product is neutral and has to undergo another eaction 
for the grafting of ionic ligands. We have thus selected, 
instead, POC13 which can act both as a cross linking and a 
functionalizing agent (Fig. 5). 
This reaction gives rise to both phosphodiester and 
monophosphate bonds. These bonds exhibit good chemical 
stability while remaining susceptible to enzymatic hydroly- 
sis [28]. The resulting material has therefore good chemical 
and physical stability while remaining biodegradable.The 
reaction performed in alkaline conditions gives rise to a 
gel of polymerized starch which structure is directly de- 
pendent upon the nature of the starting polysaccharide and 
upon the cross linking conditions. The mechanical strength, 
the mesh size and the ionic character can thus be adjusted 
in view of a specific application. The conditions elected 
give rise to a polymerized gel which affords directly 
monodispersed 20 nm population, after a high pressure 
homogenization step, avoiding then the need for any fur- 
ther sizing treatment. The 20 nm particles obtained can be 
easily washed free of salts and secondary material by 
precipitation with methanol. Both the cross linking reac- 
tion of starch and the high pressure homogenization step 
present strong similarities with analogous reactions per- 
formed in the modified starch [29] and dairy industries 
[30]. This similarity augurs favorably of the ruggedness of 
the process and of the availability of industrial processing 
equipment. 
Acylation reactions of polysaccharides are normally 
carried out in polar solvents such as pyridine, DMF or 
DMSO [31] which have the ability to solubilize both the 
polysaccharide and the fatty acid reagent. In these condi- 
tions, the acylation is homogeneous within the polysaccha- 
ride matrix and is not restricted to the outer part of the 
Table 4 
Efficiency of the gentamicin and doxorubicin entrapment within SMBV 
Drug ~ Ac. core a Phospholipids ~ Non entrappeddrug Entrapment yield Drug/SMBV SMBVs diameter 
(mg) (mg) (rag) (mg) (%) (w/w)  (nm) 
before loading after loading 
Gentamicin 10.5 35 35 < 0.5 95 0.14 21 + 5 21 + 5 
Doxorubicin 150 500 500 45 + 3 70 0.11 21 ± 5 n.d. b 
a Amount initially involved. 
t, Not determined. 
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S" 
O-- i  ~ O" Na ÷ 
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1 ) NaOH Monophosphate ester bond 
Soluble pol~fsaccharide 
2 ) PO Cl 3 Phosphodiester bond 
Fig. 5. Reaction of polysaccharides with POC13. The reaction gives rise to both monophosphate and phosphodiester bonds. 
panicle. If, on the other hand, the reaction is carried out in 
a non polar solvent, with the ability to solubilize the fatty 
acid reagent, but not the polysaccharide, then the reaction 
is obviously limited to the surface of the polysaccharide 
particle. This is notably confirmed by the results of the 
acylation performed in CH2C12 with polysaccharide parti- 
cles dried with conventional techniques and which indicate 
a very low amount of grafted fatty acids even after several 
acylation steps (Fig. 2). This very low amount can be 
explained, on one hand, by the inability of the non-polar 
solvent to solubilize the polysaccharide particles and on 
the other hand by the fact that the particles, when dried 
conventionally, are heavily aggregated and the solvent is 
thus prevented to have access to the entire surface area of 
the particles (Fig. 6). Non-aggregative drying obtained 
through the addition of NH4HCO 3 allows a better access 
of the solvent o the surface of the particles and gives rise 
to a corresponding higher percentage of fatty acid grafted, 
notably after several acylation steps. 
Drying in presence of 
Conventionnal drying 
HCO3" , NH4* 
Aggregated Polysaccharide particles Non aggregated Polysaccharide 
particles 
I ; 
l_ Heterogenous Homogenous grafting grafting 
Fig. 6. Schematic representation f external acylation of polysaccharide 
cores performed after conventional drying or after drying in the presence 
of NH4HCO 3. 
The lack of stability has proved to be a major difficulty 
in the use of liposomes [32]. We therefore undertook a 
study to evaluate the stability of SMBVs, notably by 
comparison with liposomes prepared in the same condi- 
tions with the same technique and with the same phospho- 
lipid composition. The increased stability of SMBVs com- 
pared to liposomes is probably due to the structuring effect 
of the lipidic layer of the polymeric ore [33] and augurs 
favourably for their pharmaceutical applications. 
SMBVs are supramolecular assemblies involving an 
internal acylated core and an external phospholipidic layer. 
The key issue is then to establish that these two compo- 
nents are indeed associated together and not merely pre- 
sent as separate ntities. A first information can be drawn 
from the size measurement of SMBVs as a function of the 
phospholipids/acylated cores ratio. These results indicate 
that in the absence of phospholipids, acylated cores alone 
aggregate heavily. The presence of amphiphilic phospho- 
lipids is thus essential to ensure the dispersion of SMBVs. 
These results are confirmed by the resonance nergy trans- 
fer experiments. These experiments rely upon the interac- 
tions which occur between two fluorophores if the emis- 
sion band of one, the energy donor, overlaps with the 
excitation band of the second, the energy acceptor. When 
the two probes exist in close spatial proximity, the energy 
from a photon absorbed by the energy donor can be 
transferred to the energy acceptor which will then fluo- 
resce as though it had been excited directly. The efficiency 
of the fluorescence energy transfer between two matching 
fluorophores i dependent upon their spatial separation [34] 
and the measure of this efficiency provides thus a means to 
evaluate the distance between the fluorophores. This ap- 
proach has notably been used successfully to monitor 
membrane fusion [35]. In our case, the results obtained 
with SMBVs bearing simultaneously a rhodamine fluo- 
rophore grafted upon the acylated cores and a NBD fluo- 
rophore incorporated in the phospholipid layer indicate 
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that rhodamine fluorescence at580 nm is indeed observed 
after NBD excitation at 470 nm. They also indicate that the 
amount of energy transfer measured through the decrease 
in the NBD emission is much larger than the amount of 
energy transfer observed with a simple mixture of rho- 
damine acylated cores and NBD liposomes. These results 
confirm that the acylated cores and the phospholipids are 
actually in close spatial proximity, in agreement with the 
proposed SMBV structure. These results, however, do not 
guarantee that some phospholipids may not be present as 
liposomes. Indeed the surface of the SMBVs is obviously 
limited and, in the case of the use of an excess of 
phospholipids, liposomes hould necessary also be present 
in the preparations. The results obtained with the gel 
permeation analysis of SMBVs as a function of the phos- 
pholipids/acylated core ratio, clearly show that liposomes 
are significantly absent from the preparations when the 
phospholipid/acylated core ratio is lower than 100% and 
that they appear above this value. 
SMBVs have been designed through their internal ionic 
core to achieve good drug entrapment. The SMBVs de- 
scribed in this paper are derived with anionic phosphate 
groups and are thus particularly well suited for the entrap- 
ment of cationic drugs. Similarly, positively derivatized 
SMBVs will be appropriate for the entrapment of anionic 
drugs. Because of the similarity between this entrapment 
mechanism and ion exchange [ 16], the aptitude of a drug to 
be satisfactorily entrapped within SMBVs and the stability 
of the entrapment could be initially approached through 
the analysis of its ion exchange chromatographic be- 
haviour. Actual entrapment capability and stability within 
SMBVs are bound however to differ somewhat according 
to the nature of the drug because of the presence of the 
lipidic membrane which brings the possibility of hy- 
drophobic interactions. Numerous drugs of various size 
and nature can be entrapped efficiently within SMBVs. 
The work performed with gentamicin, indicate that the 
drug, because of its polycationic structure, has a very 
strong affinity for the anionic cores of SMBVs, and gives 
rise to an extremely efficient entrapment. It has indeed 
proved difficult to quantatively release gentamicin from 
SMBVs and the determination f the entrapment had to be 
done by measuring the amount of non entrapped drug. It is 
also interesting to note that the loading of the drug does 
not modify the diameter of the biovector and hence should 
not affect its biodistribution. The strength of the interac- 
tions between gentamicin and SMBVs will probably en- 
sure satisfactory entrapment stability of the antibiotic in 
plasm and its slow release only after cell internalization 
and lysosomal degradation of the carrier. Because of the 
high toxicity of aminoglycosides and because of their poor 
efficiency for achieving high intracellular concentration, 
this property could be used advantageously in the treat- 
ment of aminoglycoside s nsitive intracellular disease [36]. 
The work performed with doxorubicin indicated that this 
monocationic drug can also be readily entrapped within 
SMBVs, although with a lower affinity compared to gen- 
tamicin. Interestingly, doxorubicin can be released from 
SMBVs using high ionic strength buffer and HPLC analy- 
sis did not indicate any degradation of the molecule. 
The use of vesicular and particular drug carriers has 
been hampered for a long time by their rapid recognition 
and removal by cells of the mononuclear phagocytic sys- 
tem (MPS). Although sterically stabilized liposomes with 
long circulation time have been described [37], the pres- 
ence of phospholipids with special head groups such as 
PEG PE [38-42] may interfere with the recognition pro- 
cess of ligands anchored at the surface of the particles. It is 
known however that size is a key parameter in phago- 
cytosis and that larger particles are taken up at a much 
higher rate than smaller particles [39]. SMBVs with their 
small diameter comparable to LDL, might provide a way 
to circumvent this problem and to allow the escape from 
the MPS while ensuring efficient argeting. 
Another central aspect regarding the feasibility of parti- 
cles as drug carriers is whether they are able to cross the 
anatomical barriers such as the capillary walls, which 
separate the extravascular compartment from the blood 
stream. Blood capillaries are classified into three different 
groups, continuous, fenestrated and sinusoidal. Only the 
sinusoidal ones offer sufficiently large gaps for drug carri- 
ers such as liposomes to penetrate the endothelium. In- 
deed, the ability of some liposome formulations to accu- 
mulate in transplantable human tumors has been attributed 
to increased microvascular permeability [40]. Thanks to 
their small size analogous to LDLs, SMBV might be 
capable of diffusing through fenestrated capillaries as well, 
increasing the probability of targeting cells in the extravas- 
cular compartment. 
The similarity between SMBV and the lipidic part of 
LDL should also allow the preparation of ApoB-SMBV 
conjugates. Indeed, it has been reported that ApoB could 
be extracted from LDL through a cold hexane and deter- 
gent technique while retaining its native conformation and 
properties after conjugation with liposomes [41]. It is 
anticipated that since LDL/antineoplastic drug complexes 
have proven to be an effective drug carrier in vivo and in 
vitro [35-37], SMBV Apo B should also prove to be an 
useful carrier for ionic drug targeting. 
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